249 related articles for article (PubMed ID: 3538253)
1. Effect of captopril on chronic puromycin aminonucleoside nephrosis in rats.
Radin MJ; Wilke WL; Fettman MJ
Res Commun Chem Pathol Pharmacol; 1986 Nov; 54(2):279-82. PubMed ID: 3538253
[TBL] [Abstract][Full Text] [Related]
2. Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
Zheng Y; Shirato I; Maeda A; Kobayashi N; Liao J; Shou I; Fukui M; Tomino Y
J Nephrol; 2002; 15(1):36-41. PubMed ID: 11936424
[TBL] [Abstract][Full Text] [Related]
3. Ameliorative effects of dietary protein restriction in chronic aminonucleoside nephrosis.
Diamond JR; Karnovsky MJ
J Lab Clin Med; 1987 May; 109(5):538-44. PubMed ID: 3572200
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glomerular visceral epithelial cell endocytosis during nephrosis induced by puromycin aminonucleoside.
Schwartz MM; Sharon Z; Pauli BU; Lewis EJ
Lab Invest; 1984 Dec; 51(6):690-6. PubMed ID: 6389977
[TBL] [Abstract][Full Text] [Related]
5. Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.
Marinides GN; Groggel GC; Cohen AH; Cook T; Baranowski RL; Westenfelder C; Border WA
Am J Pathol; 1987 Nov; 129(2):394-401. PubMed ID: 2823616
[TBL] [Abstract][Full Text] [Related]
6. Effect of a low-protein diet on expression of non-muscle type myosin heavy-chain isoforms in glomeruli of rats with puromycin aminonucleoside nephrosis.
Koide H; Nakamura T; Kimura K; Ebihara I; Nagai R; Tomino Y
Nephrol Dial Transplant; 1996 Sep; 11(9):1769-74. PubMed ID: 8918620
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
Takashima K; Nishiyama C; Arisaka N; Takahashi T; Souma S; Tsuda M; Hayashi M; Kasahara H; Kodama H; Tamura T; Murakami M; Kuroda J; Sato F
Arzneimittelforschung; 2009; 59(2):79-85. PubMed ID: 19338138
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of 35sulfate into the glomerular basement membrane in puromycin aminonucleoside nephrosis.
Garin EH; Boggs KP; Burke FC
Int J Pediatr Nephrol; 1985; 6(2):117-20. PubMed ID: 4030221
[TBL] [Abstract][Full Text] [Related]
9. DMSO potentiates aminonucleoside of puromycin nephrosis in rats.
Spear GS; Nguyen D; Conklin S; Wikle JS; Fan J; Lan YH; Allen J; Reineck S
J Pathol; 1987 Oct; 153(2):183-7. PubMed ID: 3694323
[TBL] [Abstract][Full Text] [Related]
10. Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.
Chiu PJ; Brown AD
Res Commun Chem Pathol Pharmacol; 1981 Mar; 31(3):419-33. PubMed ID: 6454943
[TBL] [Abstract][Full Text] [Related]
11. The effect of captopril on urinary protein excretion in puromycin aminonucleoside nephrosis in rats.
Trachtman H; Zavilowitz B; Bennett B; Goldsmith DI
Pediatr Res; 1985 Aug; 19(8):828-34. PubMed ID: 3898001
[TBL] [Abstract][Full Text] [Related]
12. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside.
Grond J; Weening JJ; Elema JD
Lab Invest; 1984 Sep; 51(3):277-85. PubMed ID: 6471809
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis.
Nakayama K; Natori Y; Sato T; Kimura T; Sugiura A; Sato H; Saito T; Ito S; Natori Y
J Lab Clin Med; 2004 Feb; 143(2):106-14. PubMed ID: 14966466
[TBL] [Abstract][Full Text] [Related]
14. Adverse effect of indomethacin in experimental chronic nephrosis.
Kleinknecht C; Laouari D; Gubler MC; Gros F
Int J Pediatr Nephrol; 1983 Jun; 4(2):83-8. PubMed ID: 6618773
[TBL] [Abstract][Full Text] [Related]
15. Glomerular epithelial detachment, not reduced charge density, correlates with proteinuria in adriamycin and puromycin nephrosis.
Whiteside C; Prutis K; Cameron R; Thompson J
Lab Invest; 1989 Dec; 61(6):650-60. PubMed ID: 2601299
[TBL] [Abstract][Full Text] [Related]
16. Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats.
Yatsu T; Aoki M; Tanaka A
Eur J Pharmacol; 2005 Mar; 510(1-2):121-6. PubMed ID: 15740732
[TBL] [Abstract][Full Text] [Related]
17. Key molecular events in puromycin aminonucleoside nephrosis rats.
Guan N; Ding J; Deng J; Zhang J; Yang J
Pathol Int; 2004 Sep; 54(9):703-11. PubMed ID: 15363039
[TBL] [Abstract][Full Text] [Related]
18. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
Ebihara I; Nakamura T; Tomino Y; Koide H
Nephrol Dial Transplant; 1997 May; 12(5):1001-6. PubMed ID: 9175058
[TBL] [Abstract][Full Text] [Related]
19. Renin-sodium profile in experimental nephrosis induced by puromycin aminonucleoside.
Sagae Y; Matsumoto Y; Unno K
J Pharmacobiodyn; 1983 Jul; 6(7):475-80. PubMed ID: 6358456
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of experimental nephrotic syndrome induced by puromicyn aminonucleoside in rats. III. Effect of captopril, an angiotensin converting enzyme inhibitor, on proteinuria and sodium retention.
Pedraza-Chaverrí J; Cruz C; Chávez MT; Ibarra-Rubio ME; Tapia E; Peña JC
Rev Invest Clin; 1990; 42(3):210-6. PubMed ID: 2270368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
